Purchase Order 75D30126P20991
- Not listed
- This firm-fixed-price purchase order was awarded by the Centers for Disease Control and Prevention (CDC) to Inbios International, Inc., a minority-owned, for-profit biotechnology company based in Seattle, Washington. The $61,575 contract is for the provision of Inbios' DETECT IgM Capture ELISA Kit and accessories, which are used for infectious disease diagnostics. The award does not have a set-aside designation. Inbios has received multiple previous federal contract and grant awards from the...
- This federal contract award by the Centers for Disease Control and Prevention (CDC) is for the procurement of ELISA detection kits from Inbios International Inc., a minority-owned, for-profit biotechnology company based in Seattle, Washington. The contract, valued at $85,485.00, is a firm fixed-price purchase order with an ultimate completion date of April 30, 2020. Inbios is a critical partner to the government, particularly during the COVID-19 pandemic, having secured numerous contracts with...
- The Department of Health and Human Services Centers for Disease Control and Prevention (HHS-CDC) in Pittsburgh awarded a $19,036 purchase order to Inbios International Inc. of Seattle, Washington for INBIOS supplies and reagents. As a prime contractor, Inbios will provide laboratory materials to support HHS-CDC's disease prevention and control efforts. The firm fixed price contract runs from August 24, 2023 through September 28, 2023 at the Inbios location in Seattle. No subcontractors or set...
- The Department of State Bureau of East Asian and Pacific Affairs awarded a firm fixed-price purchase order to Inbios International Inc., a minority-owned, for-profit biotechnology company based in Seattle, Washington, for $143,218.00. The contract is for the supply of CDC 7553.0/ELISA detection kits, which are immunodiagnostic devices used for infectious disease testing. Inbios has a history of federal contract awards and grants related to the development and manufacture of diagnostic tests,...
- The U.S. Department of Health and Human Services, specifically the Office of the Assistant Secretary for Preparedness and Response, awarded a $20,736,000 firm-fixed-price definitive contract to Inbios International Inc., a minority-owned, for-profit biotechnology company based in Seattle, Washington. The contract is for the delivery of over-the-counter COVID-19 tests. The performance period is from September 20, 2023, to March 19, 2025. This contract has no set-aside designation, indicating...
- This federal contract award to Inbios International Inc., a minority-owned business based in Seattle, Washington, was issued by the Office of the Assistant Secretary for Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS). The $749,998 firm fixed-price contract supports research and development (R&D) of an antibody diagnostic for COVID-19. The contract was issued under a Broad Agency Announcement (BAA) solicitation from ASPR's Division of...
- This is a $12,670,301.06 firm fixed-price definitive contract awarded by the U.S. Department of Health and Human Services (DHHS) Biomedical Advanced Research and Development Authority (BARDA) to Inbios International, Inc., a minority-owned, for-profit biotechnology company based in Seattle, Washington. The contract is for the production capacity expansion of COVID-19 diagnostic tests and was awarded under Contracting Opportunity FA7013-20-S-0002, which did not have a set-aside designation....
- The U.S. Department of Health and Human Services' Office of the Assistant Secretary for Preparedness and Response awarded a cost-plus-fixed-fee definitive contract worth $7,735,010.61 to Inbios International Inc., a minority-owned, for-profit biotechnology company based in Seattle, Washington. The contract is for the development of point-of-care and laboratory-based immunoassays for the presumptive diagnosis of Zika virus infection. This contract is not set aside. Inbios is a key partner to...
- This federal contract award, valued at $4,708.00, was issued by the Medical Supply Chain division of the Defense Logistics Agency (DLA) to Inbios International Inc., a minority-owned biotechnology company based in Seattle, Washington. The contract is for the procurement of "TEST KIT,VISCERAL L" and has a completion date of June 24, 2024. Inbios International Inc. is a veteran-owned, for-profit organization that specializes in the design, development, and manufacture of immunodiagnostic...
- This $806,303.37 cost-plus-fixed-fee delivery order contract was awarded by the Department of the Army Medical Command to Inbios International Inc., a minority-owned, for-profit biotechnology company based in Seattle, Washington. The contract is for other direct costs and does not have a set-aside designation. Inbios International specializes in the design, development, and manufacture of immunodiagnostic devices, and has received over $85 million in prime contract awards from agencies like...
The Centers for Disease Control and Prevention (CDC) Atlanta, operating through its Pittsburgh division, awarded a firm fixed-price purchase order valued at $62,258.00 to Inbios International Inc. for inbios reagents kits. The contract was awarded on April 20, 2026, with an ultimate completion date of May 19, 2026, and represents a direct procurement without a set-aside designation. Performance will be conducted at the vendor's facility in San Juan, Puerto Rico. Inbios International Inc., a Seattle-based, minority-owned biotechnology company, specializes in the design, development, and manufacture of immunodiagnostic devices for infectious diseases and has established itself as a critical federal partner through numerous contract awards with health and defense agencies. This procurement aligns with Inbios's core competencies in producing diagnostic test kits and reagent solutions for infectious disease detection. The company's extensive track record includes multiple federal contracts ranging from small purchase orders to substantial agreements exceeding $52 million, with particular prominence during the COVID-19 pandemic response. Inbios has demonstrated expertise in rapid diagnostic testing, immunodiagnostic device development, and production scaling, supported by federal grant funding from agencies including the National Institute of Allergy and Infectious Diseases for advancing diagnostic capabilities for neglected tropical diseases and emerging infectious diseases.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $62.3k | 4/15/26 |